



Prof. Volker Auwärter

Contact

Prof. Volker Auwärter
Germany

Publications (7)

Grumann C, Huppertz L, Bisel P, Angerer V, Auwärter V. Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). *Drug Testing and Analysis* 2019; Epub ahead of print

Moosmann B, Bisel P, Westphal F, Wilde M, Kempf J, Angerer V, Auwärter V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). *Drug Test Anal* 2019; 11:541-549.

Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V. 5F-Cumyl-PINACA in 'e-liquids' for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. *Forensic Toxicol* 2018; 37:186-196.

Mogler L, Franz F, Wilde M, Huppertz L, Halter S, Angerer V, Moosmann B, Auwärter V. Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples. *Drug Test Anal* 2018; 10:1417-1429.

Moosmann B, Auwärter V. Designer Benzodiazepines: Another Class of New Psychoactive Substances. In: *New Psychoactive Substances*. Springer, Cham, 2018. pp. 383-410.

Mogler L, Moosmann B, Kassiou M, Banister S, Longworth M, Weinfurtner G, Angerer V, Rentsch D, Franz F, Auwärter V. Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. *Drug Test Anal* 2017; 10:196-205.

Huppertz L, Moosmann B, Auwärter V. Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. *Drug Test Anal* 2017; 10:206-211.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch